Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Interest Expense

Cost of servicing the company's debt during the period.

Cardiff Oncology, Inc.NASDAQ: CRDF

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How CRDF compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Interest expense amounts to 0.0% of revenue for CRDF, versus a peer median of 64.3%.
CRDF Competitors
Interest Expense for CRDF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$7.04M USD+93.1%—394.5%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$2.04M USD-56.5%+39.2%64.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$1.36M USD+128.9%-32.0%—
IPHAInnate Pharma S.A.FY2025€440K EUR-22.3%+15.2%15.8%
MOLNMolecular Partners AGLTM Mar 2026CHF 45.01K CHF+45.1%-69.7%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$0 USD——0.0%
FBRXForte Biosciences, Inc.LTM Mar 2026$0 USD———
PEPGPepGen Inc.LTM Mar 2026$0 USD———
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD-100.0%——
Peer median (excluding CRDF) —+11.4%-8.4%64.3%

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue359K386K488K683K593K
Cost of Revenue00000
Gross Profit359K386K488K683K593K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development17.38M27.11M32.86M36.85M35.33M
Selling, General & Admin11.84M13.18M13.04M12.48M14.22M
Operating Expenses29.21M40.29M45.9M49.33M49.55M
Depreciation & Amortization451K236K398K404K904K
EBITDA(27.84M)(38.47M)(41.04M)(45.03M)(44.95M)
EBITDA Margin-7754.9%-9965.8%-8410.5%-6592.5%-7579.6%
Operating Income(28.86M)(39.9M)(45.41M)(48.65M)(48.96M)
Operating Margin-8037.6%-10337.3%-9305.7%-7123.1%-8256.3%
Interest Income264K1.58M4.07M3.26M3.1M
Interest Expense00000
Other Income / Expenses564K1.2M3.97M3.22M3.11M
Income Before Tax(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Pre-Tax Margin-7880.5%-10026.9%-8492.0%-6651.7%-7732.0%
Income Tax Expense00000
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Net Margin-7880.5%-10026.9%-8492.0%-6651.7%-7732.0%
EPS (Basic)(0.73)(0.89)(0.93)(0.95)(0.69)
EPS (Diluted)(0.73)(0.89)(0.93)(0.95)(0.69)
Weighted Avg Shares39.03M43.6M44.68M47.65M66.84M
Weighted Avg Shares (Diluted)39.03M43.6M44.68M47.65M66.84M

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.